- Home
- GHG vs RIGL Comparison
GHG vs RIGL Comparison
Compare GHG & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHG
- RIGL
- Stock Information
- Founded
- GHG 2004
- RIGL 1996
- Country
- GHG China
- RIGL United States
- Employees
- GHG N/A
- RIGL N/A
- Industry
- GHG Hotels/Resorts
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- GHG Consumer Discretionary
- RIGL Health Care
- Exchange
- GHG Nasdaq
- RIGL Nasdaq
- Market Cap
- GHG 202.0M
- RIGL 335.5M
- IPO Year
- GHG 2018
- RIGL 2000
- Fundamental
- Price
- GHG $2.34
- RIGL $18.98
- Analyst Decision
- GHG
- RIGL Buy
- Analyst Count
- GHG 0
- RIGL 5
- Target Price
- GHG N/A
- RIGL $36.40
- AVG Volume (30 Days)
- GHG 11.9K
- RIGL 206.5K
- Earning Date
- GHG 08-14-2025
- RIGL 08-05-2025
- Dividend Yield
- GHG 4.35%
- RIGL N/A
- EPS Growth
- GHG N/A
- RIGL N/A
- EPS
- GHG 0.15
- RIGL 2.08
- Revenue
- GHG $184,055,595.00
- RIGL $203,077,000.00
- Revenue This Year
- GHG $19.02
- RIGL $14.41
- Revenue Next Year
- GHG $8.26
- RIGL $15.97
- P/E Ratio
- GHG $16.17
- RIGL $9.41
- Revenue Growth
- GHG N/A
- RIGL 70.16
- 52 Week Low
- GHG $1.93
- RIGL $8.10
- 52 Week High
- GHG $3.40
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- GHG 59.62
- RIGL 45.79
- Support Level
- GHG $1.97
- RIGL $18.24
- Resistance Level
- GHG $2.40
- RIGL $19.38
- Average True Range (ATR)
- GHG 0.11
- RIGL 0.77
- MACD
- GHG 0.03
- RIGL -0.04
- Stochastic Oscillator
- GHG 76.00
- RIGL 43.64
About GHG GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share
GreenTree Hospitality Group Ltd is a franchised hotel operator in China as franchised and managed hotels represent almost all the hotels in its hotel network. The hotel network of the company comprised approximately 4,059 hotels with nearly 302,497 rooms in China, covering all centrally administrated municipalities and cities throughout all provinces and autonomous regions in China. The company operates its hotels under GreenTree Inns, GreenTree Eastern, Gme, Gya and VX, GreenTree Alliance, Vatica, and others. The company operates solely in China and generates all its revenue from China itself.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.